AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 312 min read$ISRG

Brosius Mark sold $20K of ISRG

Brosius Mark (EVP & Chief Mfg and Supply Cha) sold 56 shares of INTUITIVE SURGICAL INC (ISRG) at an average of $348.92 ($346.83–$351.00) across 2 trades over 2026-07-30 to 2026-07-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brosius Mark
Published Jul 31, 2026, 9:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 10:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The only new fact is the reported open-market sale by an officer (EVP and Chief Mfg and Supply Chain) totaling about $19.5K across two trades, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and small dollar amount make it low-signal for price discovery.

03

What to watch

The sale size is small relative to a mega-cap, and the filing does not disclose any new operational or financial information.

Relevance 2/10Novelty 3/10Timing: filed 2026-07-31 after-hours

Background

The article is an SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG).

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Form 4 shows ISRG EVP Mark Brosius sold 56 shares in two open-market trades for about $19.5K under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price reaction; any effect is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is an insider transaction, not an earnings, guidance, deal, or regulatory event. The presence of a pre-arranged 10b5-1 plan reduces interpretive value.

Market effects

Sector

No direct sector read-through; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can still reflect personal liquidity needs rather than bearish expectations, so the market may ignore it.

Key entities

  • public_company
    ISRG

    Intuitive Surgical, issuer of the Form 4 insider transaction.

  • insider
    Brosius Mark

    Officer (EVP and Chief Mfg and Supply Chain) who sold shares.

Read at source← All news

Related articles

JUL 28
$ISRGMed

UBS starts medtech coverage, favors Intuitive Surgical and Enovis By Investing.com

UBS initiated coverage of four U.S. medtech firms. It assigned Buy ratings to Intuitive Surgical (ISRG) with a $500 price target and Enovis (ENOV) with a $51 target, citing growth drivers and improving fundamentals. UBS gave Inspire Medical Systems (INSP) a Sell rating with a $39 target and Integra LifeSciences (IART) a Neutral rating with a $19 target, citing competition, reimbursement and limited catalysts.

investing.com4 min
JUL 27
$UNHMed

UnitedHealth Group Incorporated (UNH) and Intuitive Surgical, Inc. (ISRG) Just Showed Why Beating Estimates Isn’t Enough

UnitedHealth (UNH) and Intuitive Surgical (ISRG) both beat July earnings estimates. UNH reported adjusted EPS of $6.38 vs $4.90 expected, revenue of $112B, and raised full-year profit guidance to $19.50-$20. ISRG reported $2.89B revenue and $2.80 EPS vs $2.50 expected, but shares fell after guidance implied slower procedure growth near the middle of its range.

yahoo.com6 min
JUL 26
$ISRGMedAI 8/10

The $100 Billion Surgery Giant That Wall Street Suddenly Doesn't Trust

Intuitive Surgical reported Q2 adjusted EPS of $2.80 vs $2.50 expected and revenue of $2.89B vs $2.82B, with 468 new da Vinci systems installed and an installed base of 11,710. Shares fell over 9% after-hours and trade near the 52-week low. Guidance for 2026 was confirmed but not raised, while analysts cited ACA subsidy changes, GLP-1 impacts, and tariffs.

ad-hoc-news.de6 min
JUL 22
$JNJMedAI 8/10

Why Johnson & Johnson Is Sending Intuitive Surgical (ISRG) Stock Down Today

Intuitive Surgical (ISRG) shares fell after Johnson & Johnson (JNJ) received U.S. FDA marketing authorization for its Ottava robotic surgical platform. The article says JNJ plans an immediate U.S. commercial rollout and faster launches in Western Europe and Japan, positioning Ottava as a competitive alternative to ISRG’s da Vinci systems. It cites ISRG down about 35% YTD and options data implying further near-term downside.

barchart.com5 min